ClinicalTrials.gg
Sign In

Drug

Anti-CTLA-4 Monoclonal Antibody IBI310 clinical trials

Also written IBI310.

studies test it
15
open now
6
in phase 3
3
first study started
2019

Keep track of what changes. Save the Anti-CTLA-4 Monoclonal Antibody IBI310 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

IBI310
10

Combined with it in one product

IBI310+ sintilimab + bevacizumab
1
IBI310+ sintilimab
1
IBI310+Sintilimab
1
sintilimab+IBI310+chemotherapy
1
IBI310+IBI308
1

Studies by the year they started

15 studies that test it; most in 2021 (4)

Studies that test Anti-CTLA-4 Monoclonal Antibody IBI310, by start year
YearStudies
20191
20203
20214
20221
20231
20241
20264

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
10
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Hepatocellular
4
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Melanoma
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1

Who runs them

Industry 9 · Other 6

Innovent Biologics (Suzhou) Co. Ltd. (8) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Peking University (2) · Shanghai Zhongshan Hospital (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1)

Often tested with

Tested in the same studies.

Sintilimab (11) · Bevacizumab (1) · Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 (1) · Cafelkibart (1) · Surufatinib (1)

Studies

Open first, then newest update. How each study uses Anti-CTLA-4 Monoclonal Antibody IBI310 is read from its arms, and is right about nine times in ten.

Testing it · 15

Given in every arm · 1 — Anti-CTLA-4 Monoclonal Antibody IBI310 is usual care beside what is tested